Development and Validation of the Hyperlipidemia: Attitudes and Beliefs in Treatment (HABIT) Survey for Physicians

Journal of General Internal Medicine

Volumn 18, Issue 12, 2003, Pages 984-990

  Foley, Kathleen A ^a   Vasey, Joseph ^b   Alexander, Charles M ^a   Markson, Leona E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Attitudes; Cholesterol; Education; Physician behavior

Indexed keywords

ANTILIPEMIC AGENT;

CLINICAL PRACTICE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG EFFICACY; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; INSTRUMENT; PHYSICIAN ATTITUDE; PROCESS DEVELOPMENT; RELIABILITY; REVIEW; STATISTICAL SIGNIFICANCE; THEORETICAL STUDY; VALIDATION PROCESS;

ATTITUDE OF HEALTH PERSONNEL; CHOLESTEROL, LDL; HUMANS; HYPERLIPIDEMIAS; PRACTICE GUIDELINES; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 0348062814     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1497.2003.30114.x     Document Type: Review

References (42)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association: 2000.
2. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
3. The Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study. Lancet. 1995;345:1274-5.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335:1001-9.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin In patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
6. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998;98:2513-9.
7. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-64.
8. Frick M, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-45.
9. Shepherd J, Cobbe S, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-7.
10. Downs J, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-22.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
12. Olson K, Bungard T, Tsuyuki R. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy. 2001;21:807-17.
13. Sueta C, Chowdhury M, Boccuzzi S, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303-7.
14. Hyman D, Maibach E, Flora J, Fortmann S. Cholesterol treatment practices of primary care physicians. Public Health Rep. 1992;107:441-8.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
16. Abookire S, Karson A, Fiskio J, Bates D. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001;161:53-8.
17. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312:1215-8.
18. Ray J. Evidence in upheaval: incorporating observational data into clinical practice. Arch Intern Med. 2002;162:249-54.
19. Yarzebski J, Bujor CF, Goldberg RJ, Spencer F, Lessard D, Gore JM. A community-wide survey of physician practices and attitudes towards cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med. 2002;162:797-804.
20. Superko H, Desmond D, de Santos V, Vranizan K, Farquhar J. Blood cholesterol treatment attitudes of community physicians: a major problem. Am Heart J. 1988;116:849-55.
21. Huse DM, Roht LH, Alpert JS, Hartz SC. Physician knowledge, attitudes and practice of pharmacologic treatment of hypertension. Ann Pharmacother. 2001;35:1173-9.
22. Larme A, Pugh J. Attitudes of primary care physicians toward diabetes. Diabetes Care. 1998;21:1391-6.
23. Anderson RM, Donnelly MB, Davis WK. Controversial beliefs about diabetes and its care. Diabetes Care. 1992;15:859-63.
24. Fix K, Oberman A. Barriers to following national cholesterol education program guidelines: an appraisal of poor physician compliance. Arch Intern Med. 1992;152:2385-7.
25. Anderson R, Donnelly M, Gressard C, Dedrick R. Development of diabetes attitude scale for health-care professionals. Diabetes Care. 1989;12:120-7.
26. Cabana M, Rand C, Powe N, et al. Why don't physicians follow clinical guidelines? JAMA. 1999;282:1458-65.
27. Ajzen I, Fishbein M. Understanding Attitudes and Predicting Social Behavior. Englewood Cliffs, NJ: Prentice Hall; 1980.
28. McBride P, Schrott H, Plane M, Underbakke G, Brown R. Primary care practice adherence to national cholesterol education program guidelines for patients with coronary heart disease. Arch Intern Med. 1998;158:1238-44.
29. Green L, Eriksend M, Schor E. Preventive practices by physicians: behavioral determinants and potential interventions. Am J Prev Med. 1988;4(4 suppl):101-7.
30. Brett AS. Psychological effects of the diagnosis and treatment of hypercholesterolemia: lessons from case studies. Am J Med. 1991;91:642-7.
31. Andrade S, Walker A, Gottleib L, et al. Discontinuation of antihyperlipidemia drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-31.
32. Aronow W. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol >125 mg/dL. Am J Cardiol. 1998;82:668-9.
33. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162:413-20.
34. Valente CM, Sobal J, Muncie HL, Levine DM, Antlitz AM. Health promotion: physician's beliefs, attitudes and practices. Am J Prev Med. 1986;2:82-8.
35. Kottke T, Foels J, Hill C, Choi T, Fendersonet D. Nutrition counseling in private practice: attitudes and activities of family physicians. Prev Med. 1984;13:219-25.
36. Ammerman AS, DeVellis RF, Carey TS, et al. Physician-based diet counseling for cholesterol reduction: current practices, determinants and strategies for improvement. Prev Med. 1993;22:96-109.
37. Pearson T, Peters T. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol. 1997;80(8B):45H-52H.
38. Shea S, Gemson D, Mossel P. Management of high blood cholesterol by primary care physicians: diffusion of the National Cholesterol Education Program Adult Treatment Panel guidelines. J Gen Intern Med. 1990;5:327-34.
39. Roberts W. Getting cardiologists interested in lipids. Am J Cardiol. 1993;72:744-5.
40. Foley K, Simpson R, Crouse J, Weiss T, Markson L, Alexander C. Effectiveness of statin titration on low density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol. 2003;92:79-81.
41. Pearson T, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project. Arch Intern Med. 2000;160:459-67.
42. Simon G, Wagner E, Vonkoff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. J Clin Epidemiol. 1995;48:363-73.